Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds a...

Full description

Bibliographic Details
Main Authors:	Elio Gregory Pizzutilo, MD, Alberto Giuseppe Agostara, MD, Laura Roazzi, MD, Rebecca Romanò, MD, Valentina Motta, PhD, Calogero Lauricella, PhD, Giovanna Marrapese, PhD, Giulio Cerea, MD, Diego Signorelli, MD, PhD, Silvio Marco Veronese, PhD, Laura Giuseppina Giannetta, MD, Andrea Sartore-Bianchi, MD, Salvatore Siena, MD
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	JTO Clinical and Research Reports
Subjects:	Case report Entrectinib Repotrectinib Resistance ROS1 F2004V
Online Access:	http://www.sciencedirect.com/science/article/pii/S266636432300098X

Similar Items

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
by: Alexander Drilon, MD, et al.
Published: (2022-06-01)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
by: Toshiaki Takakura, MD, et al.
Published: (2023-06-01)

Development of Neuropathic Arthropathy With Entrectinib: Case Report
by: Nicholas P. Giustini, MD, et al.
Published: (2022-11-01)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
by: Katsuhiro Yoshimura, MD, PhD, et al.
Published: (2021-11-01)

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib
by: Wen-Chi Wu, et al.
Published: (2023-01-01)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
by: Ryo Toyozawa, MD, et al.
Published: (2020-03-01)

Long-Term Recurrence of Completely Resected NSCLC
by: Katsuhiro Masago, MD, PhD, et al.
Published: (2020-09-01)

RET Fusion Testing in Patients With NSCLC: The RETING Study
by: Esther Conde, MD, PhD, et al.
Published: (2024-04-01)

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060
by: Takehiro Tozuka, MD, et al.
Published: (2024-04-01)

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
by: Akira Hamada, MD, et al.
Published: (2022-05-01)

Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer
by: Giulio Metro, et al.
Published: (2023-11-01)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
by: Yuhei Kinehara, MD, PhD, et al.
Published: (2023-11-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
by: Véronique Hofman, MD, PhD, et al.
Published: (2023-02-01)

Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
by: Yuki Katayama, MD, PhD, et al.
Published: (2024-03-01)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
by: Kiichiro Ninomiya, MD, PhD, et al.
Published: (2021-01-01)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
by: Tomoki Kuge, MD, et al.
Published: (2023-05-01)

Detection of Tumor DNA in Bronchoscopic Fluids in Peripheral NSCLC: A Proof-of-Concept Study
by: Gwenaëlle Arhant, MD, et al.
Published: (2024-02-01)

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
by: Hitomi Jo, MD, PhD, et al.
Published: (2023-04-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
by: Daichi Fujimoto, MD, et al.
Published: (2022-02-01)

Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
by: Satoru Miura, MD, PhD, et al.
Published: (2023-03-01)

Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases
by: Marcin Nicoś, PhD, et al.
Published: (2022-12-01)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
by: Junko Tanizaki, MD, PhD, et al.
Published: (2023-12-01)

Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy
by: Takehito Shukuya, MD, PhD, et al.
Published: (2022-05-01)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
by: Hidetoshi Hayashi, MD, PhD, et al.
Published: (2023-04-01)

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
by: Motoko Tachihara, MD, PhD, et al.
Published: (2023-10-01)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
by: Yuto Terashima, MD, et al.
Published: (2023-11-01)

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
by: Makoto Nishio, MD, PhD, et al.
Published: (2022-04-01)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
by: Liesbeth M. Hondelink, MD, et al.
Published: (2021-12-01)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
by: Makoto Hibino, MD, et al.
Published: (2022-12-01)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
by: Kazuto Nishio, MD, PhD, et al.
Published: (2021-06-01)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
by: Shiting Xu, MD, et al.
Published: (2022-04-01)

A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
by: Kazushige Wakuda, MD, et al.
Published: (2023-12-01)

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
by: Jordi Remon, MD, et al.
Published: (2020-09-01)

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
by: So Yeon Kim, MD, et al.
Published: (2022-09-01)

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01)

Prognostic Significance of the Proposed Residual Tumor Classification in Patients With NSCLC After Sleeve Lobectomy
by: Tao Chen, PhD, et al.
Published: (2023-10-01)

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
by: Giannis Mountzios, MD, PhD, et al.
Published: (2023-01-01)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
by: Jean-Louis Pujol, MD, PhD, et al.
Published: (2021-11-01)

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets
by: Bingnan Zhang, MD, MBA, et al.
Published: (2024-02-01)